Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gastrointestinal Cancer Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MUC17 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MUC17 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View MUC17 Products |
| Gene Delivery | MUC17 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based assays. |
View MUC17 Products |
| Benchmark Ab | Anti-MUC17 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences (e.g., AMG 199 analog). |
View MUC17 Products |
| Validator | MUC17 siRNA Set Target-specific knockdown verification in target-expressing cancer lines. |
View MUC17 Products |
| Related Target A | CD3E (CD3 epsilon) Essential co-target for MUC17-targeting bispecific T-cell engagers (TCEs). |
View CD3E Products |
| Related Target B | CLDN18.2 (Claudin 18.2) Synergistic gastric cancer cell-surface marker for combination or dual-targeting strategies. |
View CLDN18.2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation Epitope Binding | HEK293 host expression ensures post-translational modifications match human tumor cells. |
| Shedding Interference Analysis | High-purity soluble ECD-Fc proteins enable accurate competitive ELISA and SPR-based inhibition assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity and functional knockdown checks. |
Live MUC17 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC17 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific tumor-associated glyco-epitopes to minimize on-target, off-tumor toxicity in healthy intestinal tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific T-Cell Engager (TCE) | Amgen (AMG 199) | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | In vitro T-cell redirection assays (Requires stable MUC17-expressing cell lines via Lentivirus) |
| Antibody-Drug Conjugate (ADC) | Preclinical programs | Colorectal Cancer, Pancreatic Cancer | Internalization assays (Requires high-purity, biologically relevant ECD-Fc proteins) |
| Monoclonal Antibody (mAb) | Academic & Biotech consortia | Solid Tumors | Selectivity profiling against other mucin submaterials (Requires purified homolog panels) |